IGFBP3

Across TCGA pan-cancer cohorts, IGFBP3 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of IGFBP3’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where IGFBP3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types IGFBP3 is over-expressed in tumor.

CCRCC, PDAC, and COAD are the cancer types where IGFBP3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGFBP3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	IV	+1.734	<.001	12	view →
PDAC	Male	All	+1.182	<.001	11	view →
COAD	All	IV	+0.847	.002	8	view →
LSCC	All	III,IV	+0.812	<.001	8	view →
HNSC	Male	III,IV	+0.475	<.001	8	view →
LUAD	Male	All	+0.431	<.001	7	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

IGFBP3–CCRCC

Open the CCRCC breakdown →